Allarity Therapeutics' subsidiary files for SPAC IPO targeting $100M base offering

Allarity Therapeutics, Inc.

Allarity Acquisition Corp. filed Form S-1 for IPO of units; base offering $100M, up to $115M with over-allotment.
ALLR Sponsor LLC, Allarity's wholly-owned sub, is sponsor and expected to hold ~25% of SPAC shares post-offering.
Jesper Hoiland, Allarity board member and former Novo Nordisk EVP, to serve as Chairman of SPAC.
SPAC to list on Nasdaq under ALLNU (units), ALLN (Class A), ALLNW (warrants); Maxim Group sole book-runner.
Offering doesn't change Allarity's working capital runway into summer 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.